中文
| Catalogue |
|
|
| Recommend Products |
Biocon Limited.
India, Manufacturer, Hits: 1523, Updated:10/22/2018
20th KM Hosur Road, Electronic City, Bangalore |
Company Profile
-
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is a fully-integrated, innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and taken differentiated Small Molecules, Novel Biologics and a range of Biosimilars (Monoclonal Antibodies, rh Insulin and Insulin Glargine) from 'Lab to Market' in India, key emerging and developed markets. It has a large portfolio of biosimilars under clinical development with three of these approved in developed markets of US, EU, Japan and Australia. Its Novel pipeline includes promising assets like Insulin Tregopil, anti-CD6 antibody and a fusion protein for immuno-oncology. Some of its key brands are INSUGEN? (rh-insulin), Basalog One? (prefilled Glargine pen), CANMAb? (Trastuzumab), KRABEVA? (Bevacizumab), BIOMAb-EGFR? (Nimotuzumab) and ALZUMAb? (Itolizumab). Follow-us on Twitter: @bioconlimited and visit www.biocon.com for more information.
Company News
- Biocon Continues to be Among Science Magazine’s Top 10 Global Employers List 10/29/2024
- Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Inject... 12/25/2023
- Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilar... 9/8/2023
- Biocon Biologics Announces Key Leadership Appointments 8/7/2023
- Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept 7/25/2023
- Biocon Biologics Expands Footprint in Emerging Markets 7/6/2023
- Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments 4/3/2023
- Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award 3/29/2023
- Biocon Biologics Recognized as a Company with Great Managers 12/23/2022
- Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited 12/6/2022